Annual report pursuant to Section 13 and 15(d)

10. Income Taxes

v3.7.0.1
10. Income Taxes
12 Months Ended
Dec. 31, 2016
Income Tax Disclosure [Abstract]  
Income Taxes

Deferred tax assets and liabilities are determined based on temporary differences resulting from the different treatment of items for tax and financial reporting purposes. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to reverse. Additionally, the Company must assess the likelihood that deferred tax assets will be recovered as deductions from future taxable income. The Company has provided a full valuation allowance on the Company’s deferred tax assets because the Company believes it is more likely than not that its deferred tax assets will not be realized. The Company evaluates the recoverability of its deferred tax assets on a quarterly basis. Currently, there is no provision for income taxes as the Company has incurred losses to date.

 

The components of loss before income taxes are as follows:

 

    Year ended December 31,  
    2016     2015  
Domestic (U.S.)   $ (12,253,271 )   $ (7,724,418 )
Foreign (U.K.)     (41,837,056 )     (4,767,363 )
Foreign (Germany)     (115,779 )     (15,690 )
Loss before income taxes   $ (54,206,106 )   $ (12,507,471 )

 

The reconciliation of income tax benefit at the U.S. corporation tax rate, being the rate applicable to the country of domicile of Xenetic Biosciences, Inc. to net income tax benefit is as follows:

 

    Year ended December 31,  
    2016     2015  
Federal   $ (18,429,763 )   $ (4,252,540 )
State     (455,191 )     (276,601 )
Increase in tax losses not recognized     9,751,401       2,238,879  
Permanent differences, net     780,836       800,891  
Mark to market     992,621       722,540  
Foreign rate differential     6,923,116       502,357  
Share-based payments, net     524,131       308,888  
Enhanced research and development tax credits     (87,151 )     (44,414 )
Net provision (benefit) for income taxes   $     $  

 

Deferred tax assets and liabilities reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets are as follows:

 

    Year ended December 31,  
    2016     2015  
Deferred tax assets:                
U.K. net operating loss carryforwards   $ 6,868,717     $ 9,402,398  
U.K. capital loss carryforwards     1,259,062       1,775,932  
U.S. federal net operating loss carryforwards     3,061,669       1,659,050  
IPR&D     6,630,745        
Share-based payments     1,534,992       1,313,226  
Enhanced research and development tax credits     796,256       852,272  
Germany net operating loss carryforwards     424,432       401,906  
U.S. state net operating loss carryforwards     749,812       422,622  
Accrued expenses     174,424       44,557  
Depreciation     3,673       25,823  
Other           4,998  
Total deferred tax assets before valuation allowance     21,503,782       15,902,784  

Valuation allowance for deferred tax assets

    (21,503,782 )     (15,324,438 )
Deferred tax liabilities:                
Indefinite-lived intangible asset     (2,918,518 )     (2,918,518 )
Debt discount           (578,346 )
Total deferred tax liabilities     (2,918,518 )     (3,496,864 )
Net deferred tax assets and liabilities   $ (2,918,518 )   $ (2,918,518 )

 

For the years ended December 31, 2016 and 2015, the Company had U.K. net operating loss carryforwards of $41.05 million and $47.01 million, respectively, U.S. federal net operating loss carryforwards of $9.75 million and $5.30 million, respectively, U.S. state net operating loss carryforwards of $9.37 million and $5.28 million, respectively, and Germany net operating loss carryforwards of approximately $1.34 million and $1.27 million, respectively. The U.K. and Germany net operating loss carryforwards can be carried forward indefinitely. The U.S. federal and state net operating loss carryforwards begin to expire in 2032.

 

The Company’s ability to use its operating loss carryforwards and tax credits generated in the U.S. to offset future taxable income is subject to restrictions under Section 382 of the United States Internal Revenue Code (the “Internal Revenue Code”). These restrictions may limit the future use of the operating loss carryforwards and tax credits if certain ownership changes described in the Internal Revenue Code occur. Future changes in stock ownership may occur that would create further limitations on the Company’s use of the operating loss carryforwards and tax credits. In such a situation, the Company may be required to pay income taxes, even though significant operating loss carryforwards and tax credits exist.

 

The Company’s ability to use its operating loss carryforwards and tax credits generated in the U.K. are subject to restrictions under U.K. tax legislation. These regulations may limit the future use of operating loss carryforwards if there is a change in ownership and a change in the nature or conduct of the business carried on by the Company, and in certain circumstances where there is a change in the nature or conduct of the business only. In such cases the carryforwards would cease to be available to set against future income.

 

The Company’s ability to use its operating loss carryforwards and tax credits generated in Germany are also subject to restrictions under German tax legislation. These regulations may limit the future use of operating loss carryforwards if there is a change in ownership. In such cases the carryforwards would cease to be available to set against future income.

 

As of December 31, 2016 and 2015, the Company did not record any uncertain tax positions. The changes to uncertain tax positions for 2016 and 2015 were as follows:

 

      Year ended December 31,  
      2016       2015  
Uncertain tax benefits as of January 1   $     $  
Gross adjustments in tax positions            
Uncertain tax positions as of December 31   $     $  

 

The Company files income tax returns in the U.S. federal tax jurisdiction and Massachusetts state tax jurisdiction, and certain foreign tax jurisdictions. The Company is subject to examination by the U.S. federal, state, foreign, and local income tax authorities for calendar tax years ending 2012 through 2016 due to available net operating loss carryforwards and research and development tax credits arising in those years. The Company has not been notified of any examinations by the Internal Revenue Service or any other tax authorities as of December 31, 2016. The Company has not recorded any interest or penalties for unrecognized tax benefits since its inception.

 

Potential 382 Limitation

 

The Company’s net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service.  The Company’s ability to utilize our net operating loss (“NOL”) and alternative minimum tax (“AMT”) and research and development credit (“R&D”) carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), as well as similar state provisions. These ownership changes may limit the amount of NOL, AMT and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively.  In general, an ownership change, as defined in Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50% of the outstanding stock of a company by certain stockholders or public groups.

 

The Company has not completed a study to assess whether one or more ownership changes have occurred since we became a loss corporation as defined in Section 382 of the Code, but we believe that it is likely that an ownership change has occurred. If we have experienced an ownership change, utilization of the NOL, AMT and R&D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of our common stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL, AMT or R&D credit carryforwards before utilization.  Until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding adjustment to the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any potential limitation will have a material impact on our operating results.

 

From time to time the Company may be assessed interest or penalties by major tax jurisdictions, namely the Commonwealth of Massachusetts. As of December 31, 2016, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. No interest and penalties have been recognized by the Company to date.

 

The Company net operating loss carryforwards are subject to review and possible adjustment by the Internal Revenue Service and are subject to certain limitations in the event of cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%.